TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Receipt of allogeneic hematopoietic cell transplant \>100 days prior to consent~* Documented cGVHD as defined by the NIH consensus criteria in at least one organ system other than the GI tract (for example, cGVHD of the oral cavity would qualify as a criterion)~* Endoscopic findings consistent with GI GVHD~* Must be able to swallow tablets~* Must be able to read and understand informed consent~* Adequate birth control methods for the duration of the study~Exclusion Criteria:~* \>500 mL/day of diarrhea on any 1 day within 3 days prior to the first dose of study drug~* GI infection~* Multi-organ failure or other condition that, in the opinion of the investigator, would compromise the patient's ability to complete the study.~* HIV seropositivity~* Pregnant or nursing female~* Use of any investigational drug to treat chronic GVHD within 28 days of the first dose of study drug~* Evidence of recurrent or progressing malignant disorder that was the indication for HCT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Control
- orBec (Type: EXPERIMENTAL): Investigational drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Butterfly Sensor With Rev K Version

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male of non-pregnant female 18 y/o or older~* American Society of Anesthesiologists Classification 1,2 or 3~* Scheduled to undergo spine or hip surgery~Exclusion Criteria:~* Pregnant or nursing~* Patients who in the investigators clinical judgement would not be suitable for research

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients undergoing spine surgery (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Health Improvement After Pregnancy (HIP) Program Randomized Control Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- must own or have daily access to one or more of the following; smart phone, tablet or laptop computer~Exclusion Criteria:~* Living greater than 100km from Kingston General Hospital~* Having an existing and long term contraindication to exercise at the time of recruitment

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: NO_INTERVENTION): Participants in this arm will receive care as per the usual standards from Kingston General Hospital and their primary care provider.
- HIP Program (Type: EXPERIMENTAL): Participants in this arm will follow the HIP Program in addition to their usual care from Kingston General Hospital and their primary care provider.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Omega-3 Fatty Acid Supplementation on Inflammatory Response in Multisystem Trauma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Multi-system blunt trauma patients~* Ages 18 through 65 years, inclusive~* Admission to ICU~* Nasogastric or nasoenteric feeding tube in place~* Intention of primary medical team to feed the patient enterally~Exclusion Criteria:~* Expected mortality within 48 hours~* Intracranial hemorrhage~* Pregnant or breast feeding~* Patient, surrogate, or physician not committed to full support~* Refractory shock~* Unable to obtain enteral access~* Presence of partial or complete mechanical bowel obstruction, or ischemia, or infarction~* Current total parenteral nutrition (TPN) use, or intent to use TPN within 7 days~* Current gastrointestinal bleeding~* Requirement for vasopressors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Omega-3 (Type: ACTIVE_COMPARATOR): 50 mg/kg per day of omega-3 fatty acids (DHA Omega-3, Martek Biosciences, Columbia, MD)
- Placebo (Type: PLACEBO_COMPARATOR): 50 mg/kg per day of vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Cerebral Oxygen Saturation on Neuropsychological Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patient~* Elective cardiac surgery with cardiopulmonary bypass~* Coronary artery disease or valvular heart disease or combination of both~* Ability and willingness to give informed consent~Exclusion Criteria:~* Pediatric patients~* Emergency surgery~* Unable to understand English~* Allergic to tape used to attach oxygen sensor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed COVID-19 positive~* Admission to ICU or step-down unit~* Age ≥ 18 years old~Exclusion Criteria:~* Stage 3 AKI by KDIGO criteria~* CKD stage 4-5~* Contraindications to Na bicarbonate therapy (e.g. met. alkalosis, severe heart failure)~* Urine pH \> 7.0

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: ACTIVE_COMPARATOR): Standard of Care treatment
- Sodium Bicarbonate (Type: ACTIVE_COMPARATOR): Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: NSAID Use in Postpartum Hypertensive Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* vaginal delivery~* diagnosis of chronic hypertension, chronic hypertension with superimposed preeclampsia~* preeclampsia without severe features~* preeclampsia with severe features gestational hypertension without severe range blood pressures~* gestational hypertension with severe range blood pressures~* singleton pregnancies~Exclusion Criteria:~* Cesarean Delivery~* no diagnosis of hypertensive disorder~* chronic or acute renal disease~* allergy to ibuprofen or acetaminophen~* lupus~* multiple order pregnancies (twins, triplets)~* Narcotic addiction/ in treatment for substance abuse/ current prescription drug user/ current use of illegal drugs

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Acetaminophen (Type: OTHER): Patients will be monitored for change in blood pressure
- NSAID (Type: OTHER): Patients will be monitored during their postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Two Bag System for Hydration in Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 1 to 18 years old~* Diabetic ketoacidosis(plasmatic glucose \> 250mg/dl, pH \< 7.3, bicarbonate \< 15mmol/L, ketonuria and glycosuria)~Exclusion Criteria:~* Patients who already received insulin in the Emergency Department.~* Patients who, because of their clinical condition, require admission to intensive care unit.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- One bag (Type: ACTIVE_COMPARATOR): IV infusion of fluids, electrolytes and dextrose using one bag
- Two bags (Type: EXPERIMENTAL): Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Radial Versus Femoral Arterial Access for Cerebral Angiography in Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 8-18 years~2. Planned cerebral or supra-aortic angiography for clinical reason~3. Positive modified Allen's test using a pulse oximeter on the index finger.~4. Radial artery axial maximal diameter of \> 2.0 mm measured on a cross-sectional B-mode ultrasound of the distal radial artery, 2-3 cm proximal to the radial styloid, at the anticipated needle puncture site -~Exclusion Criteria:~1. Age \<8 years~2. Radial artery internal maximal of diameter 2.0 mm or less (measured on cross-sectional ultrasound 2-3 cm proximal to the radial styloid at the planned puncture site) - these patients would be converted to femoral access without radial artery puncture but would be assessed in the radial artery group as part of an intention-to-treat analysis.~3. Conversion to intervention (as opposed to diagnostic cerebral angiogram) during the procedure, as this will likely require a larger (femoral) access sheath; again such patients will still be assessed as part of the intention-to-treat analysis.~4. Failed modified Allen's test with pulse oximetry~   -

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- transfemoral access (Type: ACTIVE_COMPARATOR): control
- transradial access (Type: ACTIVE_COMPARATOR): case

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nasal High Flow to Maintain the Benefits of Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic obstructive pulmonary disease stage III to IV;~* With or without long-term oxygen therapy;~* Having completed a course of pulmonary rehabilitation within the last 4 weeks (at least 18 sessions).~Exclusion Criteria:~* Did not complete a course of pulmonary rehabilitation;~* Using noninvasive ventilation or constant positive airway pressure treatment;~* Tracheostomy;~* Nasal high flow intolerance;~* Pregnancy or likely to be;~* Unable to consent;~* Patients under guardianship.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Nasal high flow (Type: EXPERIMENTAL): Following baseline assessment, patients randomized to the nasal high flow arm will be equipped with a nasal high flow device (myAIRVO2) administrated through the Optiflow nasal canula. Flow will be set at the highest flow tolerated (20-30 L/min): initially 30 L/min, progressively decrease if not tolerated. Temperature will be set between 34-37°C according to the tolerance : initially 37°C and decreased if not tolerated. Patients will be asked to use the device 8h per day.~Patients under long-term oxygen will preserve their usual flow. The usual prescribed oxygen flow will then be titrated during nasal high flow to maintain the same baseline transcutaneous oxygen saturation as their conventional oxygen therapy (≥ 90%) to prevent any oxygen dilution effect of nasal high flow.
- Usual care (Type: NO_INTERVENTION): Patient randomized to the control group will have no other specific intervention than their usual care.~Patients under long-term oxygen will preserve their usual flow.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Monitoring of Advanced Colorectal Cancer With 18F-FDG PET/CT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 40 to 80 years old~* Language spoken: Finnish or Swedish~* Performance status: Karnofsky score 70 or better or WHO performance status 2 or better~* earlier diagnosed (histologically confirmed) colorectal cancer with discovered metastases at operation~* Earlier diagnosed and treated colorectal cancer with discovered recurrence in the follow up~* Mental status: Patients must be able to understand the meaning of the study~* Informed consent: The patient must sign the appropriate Ethical Committee (EC) approved informed consent documents in the presence of the designated staff~Exclusion Criteria:~* Prior medical history: Patient must have no history of serious cardiovascular, liver or kidney disease~* Vulnerable study subjects such as described in Finnish law concerning clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Colorectal cancer (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Edwards Cardioband System ACTIVE Pivotal Clinical Trial (ACTIVE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years;~* Clinically Significant Functional Mitral Regurgitation (MR);~* Symptomatic heart failure;~* Patient hospitalized due to heart failure during 12 months prior to submission to Central Screening Committee OR elevated Brain Natriuretic Peptid (BNP);~* Patient is able and willing to give informed consent and follow protocol procedures, and comply with follow-up visit compliance.~Exclusion Criteria:~* Primarily degenerative MR;~* Mitral annular calcification that would impede implantation of device;~* Other severe valve disorders requiring intervention;~* Mitral valve anatomy which may preclude proper Edwards Cardioband deployment;~* Life expectancy of less than twelve months;~* Patient is participating in concomitant research studies of investigational products which have not reached their primary endpoint;~* Unwillingness or inability to undergo follow-up investigations/visits;~* Other medical, social, or psychological conditions that precludes appropriate consent and follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Randomized - Edwards Cardioband System (Type: EXPERIMENTAL): Transcatheter mitral valve repair with the Edwards Cardioband System plus guideline directed medical therapy (GDMT)
- Randomized - Control (Type: ACTIVE_COMPARATOR): Guideline directed medical therapy (GDMT)
- Roll-In - Edwards Cardioband System (Type: EXPERIMENTAL): Transcatheter mitral valve repair with the Edwards Cardioband System plus guideline directed medical therapy (GDMT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect of Gabexate Mesilate in the Hepatocyte Protection After Liver Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All liver tumors that require resection of more than two segments of the liver.~* Age ≥20 and ≤80~* General performance status: the Karnofsky score\> 70% or ECOG 0-1~Exclusion Criteria:~* Hepatic duct reconstruction was performed~* ASA (American society of anesthesiologists' physical status classification) score: ≥3~* Patients with drug or alcohol addiction~* Patients showing low compliance~* Patients who not want to involve the clinical trial~* Patients who are unable to read or understand the informed consent, sign a consent form (eg, mental retardation, blindness, illiteracy, foreign, etc.)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo group (Type: PLACEBO_COMPARATOR): hepatectomy without Gabexate Mesilate
- Preoperative Gabexate Mesilate group (Type: EXPERIMENTAL): Gabexate Mesilate administered from the preoperative day
- Intraoperative Gabexate Mesilate group (Type: EXPERIMENTAL): Gabexate Mesilate administered from the operative day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Recovery of Performance, Muscle Damage and Neuromuscular Fatigue Following Muscle Power Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* No recent history of musculoskeletal injury~* No use of ergogenic supplements and drugs~* No use of anti-inflammatory and antioxidant supplements (\> 6 months)~* No participation at intense eccentric exercise for at least 3 days before protocols~Exclusion Criteria:~* Recent history of musculoskeletal injury~* Use of ergogenic supplements and drugs~* Use of anti-inflammatory and antioxidant supplements (\< 6 months)~* Participation at intense eccentric exercise for at least 3 days before protocols

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Core exercises protocol (Type: EXPERIMENTAL): Participants will perform 4 core exercises
- Structural exercises protocol (Type: EXPERIMENTAL): Participants will perform 4 structural (Olympic lifting) exercises
- Accentuated eccentric load exercises protocol (Type: EXPERIMENTAL): Participants will perform 4 exercises with eccentric loading
- Control condition (Type: OTHER): Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effects of LUNII on Pre-operative Anxiety and on the Post-operative Period in Children With Cleft Lip and Palate Admitted for Alveolar Bone Graft: Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 4 to 6 years.~* Alveolar bone graft with iliac crest donor site in children with unilateral or bilateral cleft lip and palate~* Primary alveolar bone graft or first side when bilateral cleft~* Followed at Necker since birth and operated according to the protocol used in the department.~* Consent signed by the holder (or holders) of parental authority~Exclusion Criteria:~* Medical care different from the usual protocol applied in the service (secondary surgery, age \> 7 years)~* Known psychomotor delay, associated rare syndrome or disease, known psychiatric disorders, other surgical procedures between hard palate closure and alveolar bone graft~* Possession and/or prior use of LUNII by the child

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- LUNII (Type: OTHER): The interactive story teller LUNII is delivered to the child the day before surgery, during the usual pre-operative medical visit.
- Without LUNII (Type: NO_INTERVENTION): Usual pre-operative visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy